Next Arc Research

Not logged in? You're viewing the Free tier. Join for free or log in to access your membership content.
Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.
Disclosure: The author does not hold a position in RXRX.
← Back to Free Index

RXRX

Analysis as of: 2026-05-14
Recursion Pharmaceuticals, Inc.
Clinical-stage biotech using an AI-native lab-and-software stack to discover, develop, and partner drug candidates.
ai automation biotech healthcare software
On Yahoo Finance ...
Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

Proof-Gated TechBio With Real Rerating Potential
The opportunity here is not just more discovery output; it is a shift from concept-like revenue to product, royalty, and better-contracted platform economics. That rerating becomes credible only if one owned asset and at least one more internal program deliver repeatable proof.

Analysis

Thesis
Recursion can rerate from a cash-backed proof story into a hybrid product-and-platform biotech if REC-4881 secures a workable registrational path and at least one more internal asset validates repeatable platform translation; that quality shift in revenue is the core 2031 value driver.
Last Economy Alignment
Cheaper cognition helps Recursion because its moat is tied to proprietary data, wet-lab throughput, and contracts rather than a thin software layer, but clinical and regulatory proof still gate value capture.
Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple
4.5x (from 5 most recent analyses)
Reasoning
The upside is a mix shift, not just bigger activity. If owned product revenue, royalties, and better-structured partner contracts replace mostly lumpy collaboration revenue, investors can assign a meaningfully better value to each dollar of sales. I still cap the multiple below premium software because this remains proof-gated biotech with regulatory friction, partner concentration, and negative cash flow today.
Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary
The core risk is that Recursion proves it can generate more experiments faster, but not more approvable medicines faster. If REC-4881 stays stuck in regulatory ambiguity and REC-1245 or another internal program fails to become a second clear human proof point, the market can keep valuing the company near cash plus option value. The good news is that capital intensity is manageable and the company still has multiple shots on goal; the bad news is that almost all of the rerating still depends on a narrow set of clinical and regulatory credibility events.
Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Last Economy Structure

AI Industrial Score
0.41
They own the labs, data, and workflow that turn AI ideas into real experiments, so better models should make their whole system more useful. The risk is that if those experiments do not turn into medicines regulators respect, the software story alone will not protect value.
Upgrade to Reader to also access: Score Decomposition, Confidence Level
Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility
Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target
$6.71
Upgrade to Reader to also access: Bull Case, Base Case, Bear Case